Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 13 of the 30 sources its claims cite were checked for support.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
CoChat Summary
TL;DR
In a single-arm trial, fecal microbiota transplantation (FMT) from anti–PD-1 responders plus pembrolizumab was well tolerated and produced clinical benefit in 6 of 15 evaluable patients with PD-1–refractory melanoma. Responders showed donor microbiome implantation, increased CD8+ T cell activation, and reduced IL-8–expressing myeloid cells.
Key findings
- Among 15 evaluable patients, objective responses occurred in 3 (20%: one complete response, two partial responses), and durable stable disease lasting >12 months occurred in another 3 (20%), for clinical benefit in 6 of 15. Median progression-free survival and overall survival were 3.0 and 7.0 months overall, and 14.0 and 14.0 months in the six patients with disease control.
- FMT caused durable gut microbiota perturbation; responders’ microbiota shifted toward donor composition, whereas nonresponders were heterogeneous. Responders also had greater donor bacteria–specific IgG responses and enrichment of taxa previously linked to anti–PD-1 response, including Firmicutes and Actinobacteria, with decreases in Bacteroidetes.
- Responders showed higher post-treatment CD56+CD8+ T cells, increased CD8+ T cell activation/differentiation markers, and more granzyme B–expressing MAIT cells. Tumor single-cell RNA sequencing showed fewer myeloid cells and regulatory T cells in responders, with lower myeloid CXCL8/IL-8 and SPP1 expression.
- Serum profiling showed responders had decreased circulating CCL2, CXCL8/IL-8, IL-18, IL-12p70, and IFN-γ, and increased IL-21, CXCL13, type II cytokines, and TNF-family cytokines. Metabolomic/lipidomic changes included more efficient primary-to-secondary bile acid conversion and altered triacylglycerol/monoacylglycerol/diacylglycerol levels. A transkingdom network of 371 nodes and 819 edges linked microbial taxa to host metabolomic and proteomic features.
Methods
- Single-arm clinical trial (NCT03341143) in patients with metastatic melanoma primary refractory to anti–PD-1. Sixteen patients were enrolled; 15 received colonoscopic FMT from seven anti–PD-1 responder donors plus pembrolizumab and were evaluable for response.
- Serial blood and stool sampling was performed, with infectious screening for 32 agents before FMT. Response was assessed by RECIST v1.1 every 12 weeks.
- Analyses included shotgun metagenomic sequencing of 223 fecal samples from recipients and donors, multiparameter flow cytometry of PBMCs, single-cell RNA sequencing of 64,340 CD45+ cells from 17 tumor samples, serum cytokine/chemokine profiling, metabolomics/lipidomics, and transkingdom network analysis.
Limitations
- The paper states that findings are preliminary and warrant evaluation in a larger randomized clinical trial; it also notes that insufficient tumor tissue was available to assess tumor mutation burden, PD-L1 expression, or IFN-γ gene expression signature as predictors of outcome.
- The text makes evident that the study is small and single-arm, limiting causal inference and comparison with standard-of-care outcomes; some analyses, such as the speed of microbiome change, did not reach statistical significance, which the authors attribute to limited sample size.
- The text also makes evident heterogeneity in nonresponders’ donor microbiota implantation and notes that nonresponse may reflect patient immunodeficiency, lack of tumor immunogenicity, absence of necessary taxa in the FMT, or failure of FMT implantation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the gut microbiome is a major tumor-extrinsic regulator of responses to anti–PD-1 (6–9).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [6] Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G, Eur. J. Immunol 45, 17– 31 (2015). 25328099 sourceExperimental — accuracy not yet measured
In 'The commensal microbiota controls the response to cancer therapy' our copy confirms that the gut microbiota modulates responses to cancer immunotherapy, chemotherapy, TBI and adoptive T-cell transfer (via myeloid-cell conditioning; see also Fig. 2 legend in Concluding remarks). But for checkpoint blockade the paper states only a hypothesis: after noting progress with anti-CTLA-4/anti-PD-1 antibodies [107], it says the data 'suggest the possibility that the microbiota may also modulate the clinical effectiveness of this new class of anticancer drugs.' The citing sentence therefore presents as an established, major regulator of anti-PD-1 responses what this source explicitly hedges as a suggested possibility, and no anti-PD-1 microbiome experiment is reported in our copy. (LLM, conf=0.78)
- Not checked yetcites [7] Finlay BB, Nat. Rev. Immunol 20, 522– 528 (2020). 32661409 source
- Partly supportedcites [8] Goldszmid RS, Cancer Immunol. Res 3, 103– 109 (2015). 25660553 PMC4324508 sourceExperimental — accuracy not yet measured
In 'Impact of commensal microbiota on cancer therapy' our copy states that 'The gut microbiota influences the response to cancer immunotherapy and chemotherapy by affecting the differentiation and functions of myeloid cells in the tumor microenvironment', and documents microbiota/antibiotic effects on CpG-ODN plus anti-IL10R, cyclophosphamide, oxaliplatin, TBI and adoptive CD8+ T-cell transfer — so the tumor-extrinsic, myeloid-priming part of the claim is supported. However, PD-1 appears only in 'Clinical perspectives' as one of the successful checkpoint approaches ('inhibition of immune checkpoints, such as CTLA-4 and PD-1/PD-L1/2'), with no linkage to microbiota; the paper instead only speculates that 'the variable response to cancer therapy observed in patients may be in part due to different microbiota composition'. Searches for 'anti-PD-1', checkpoint-blockade response and microbiota-control-of-checkpoint-efficacy returned no passage tying the microbiome to anti–PD-1 outcomes, so the specific anti–PD-1 qualifier of the claim is not supported by this source (it likely rests on the other references in the cluster 6–9). (LLM, conf=0.72)
- Could not verifycites [9] Zarour HM, Clin. Cancer Res 22, 1856– 1864 (2016). 27084739 PMC4872712 sourceExperimental — accuracy not yet measured
Our copy of Zarour (2016) is complete and discusses tumor-extrinsic drivers of anti-PD-1 response only in terms of the tumor microenvironment: soluble mediators (IL-10, IDO, VEGF-A, adenosine/A2aR, CSF-1R), suppressive cells (Tregs, TAM/MDSC), metabolic checkpoints (hypoxia/HIF-1α) and mutational/neoepitope burden correlating with clinical response (Therapeutic Strategies section). No passage mentions the gut microbiome, microbiota, or antibiotics; searches for 'gut microbiome/microbiota regulates response to anti-PD-1', 'microbiota composition antibiotic impact immunotherapy efficacy tumor-extrinsic', and 'bacterial composition fecal transplant' returned only TME-related and reference-list passages. The paper therefore neither supports nor contradicts the attributed claim. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that successful implantation and mucosal trans-location of the transplanted bacteria, known to induce an IgG response against commensal bacteria, may preferentially occur in Rs (18).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant induces persistent perturbation of recipients’ gut microbiome
What the sources say
- Supportedcites [18] Zeng MY, Immunity 44, 647– 658 (2016). 26944199 PMC4794373 source
The clause the citation is offered for is the background fact that mucosal translocation of gut bacteria is what induces an IgG response against commensal bacteria; the 'preferentially occur in Rs' inference is the citing authors' own conclusion from their FMT data and is not attributed content. Our copy states exactly that mechanism: the Results section 'Homeostatic Induction of Systemic IgG to Gram-Negative Symbiotic Bacteria' concludes that a selective group of gram-negative symbiotic bacteria breach the intestinal epithelial barrier and disseminate systemically to induce IgG, backed by detection of bacterial 16S rRNA in spleens/MLNs and Enterobacteriaceae being the predominant translocated families, and the Introduction/Discussion describe translocation-driven systemic IgG to symbiotic (commensal) bacteria. The only slippage is contextual — Zeng et al. studied resident murine symbionts under homeostatic conditions, not donor/transplanted bacteria or FMT responders — but the mechanism attributed to this source is stated there. (LLM, conf=0.82)
hedgedstates a possible causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“administration of certain gut commensals or fecal microbiota transplantation (FMT) promotes anti–PD-1 efficacy in melanoma-bearing mice (10–12).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s FMT experiments (Fig. 4G–I; page unavailable) report reduced tumor growth and improved response to anti-PD-L1 therapy in mice receiving stool from patients who responded to anti-PD-1, compared with stool from nonresponders. Our copy does not report administering individual gut commensals to mice or testing anti-PD-1 efficacy in those mice. (LLM, conf=0.90)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the indexed copy (section labeled Abstract; no page given), fecal transfer from responding patients improved tumor control in melanoma-bearing mice, and anti–PD-L1 treatment was effective in mice colonized with responder microbiota. The mouse experiment tested anti–PD-L1, not anti–PD-1; the copy also does not show that administering individual commensal species improved checkpoint-treatment efficacy in those mice. (LLM, conf=0.88)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mice, composition of the gut microbiome modulates therapeutic activity of anti–PD-1 and anti–programmed death-ligand 1 (PD-L1)”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 source
The mouse FMT experiments (Results, Fig. 4G–I passage) state that germ-free mice transplanted with stool from anti–PD-1 responders had significantly reduced tumor growth (p=0.04) versus NR-FMT recipients, and that 'mice transplanted with R-FMT also exhibited improved responses to anti-PD-L1 therapy (Fig. 4I) in contrast to mice that were transplanted with stool from NR (NR-FMT)' — i.e. microbiome composition modulated therapeutic activity of both agents in mice. The abstract likewise reports enhanced anti-tumor immunity 'in germ-free mice receiving fecal transplants from responding patients,' and the closing discussion generalizes to modulation of anti–PD-1 response. The claim's mouse-only scope matches what the paper demonstrates causally in mice. (LLM, conf=0.87)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
Our copy supports the anti–PD-L1 half of the claim with the paper's own in vivo data: in germ-free mice reconstituted with fecal material from responder versus nonresponder patients, 'Anti–PD-L1 was markedly efficacious in mice colonized with R microbiota yet completely ineffective in NR-derived mice (Fig. 3F)' (Results, Abstract section), and the Abstract states reconstitution with responder feces gave 'greater efficacy of anti-PD-L1 therapy'. However, this study did not administer anti–PD-1 to mice — its patient-level anti–PD-1 association is clinical (42 metastatic melanoma patients), and the mouse evidence for microbiome modulation of anti–PD-1 is explicitly credited to other work: 'Two additional studies have identified an association of the commensal microbiome with anti–PD-1 mAb efficacy in different solid cancers (7,14)... fecal transfer from R versus NR patients to GF mice was also able to recapitulate the patient phenotype' (Discussion). The intro likewise frames the mouse microbiome/anti–PD-L1 precedent as preclinical studies of reference (4). The attribution of the anti–PD-1-in-mice component to this source is therefore not supported by it. (LLM, conf=0.80)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple circulating cytokines and chemokines decreased after FMT in Rs, including CCL2 (MCP1), CXCL8 (IL-8), and IL-18 that have been associated with negative outcomes to anti–PD-1 (32, 33), and IL-12p70 and IFN-γ (Fig. 4A, heatmap).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant alters serum metabolome and cytokines in responders
What the sources say
- Could not verifycites [32] Gok Yavuz B, Sci. Rep 9, 3172 (2019). 30816272 PMC6395633 sourceExperimental — accuracy not yet measured
Our copy of Yavuz et al. (2019) is an in vitro study of cancer-associated fibroblasts educating CD14+ monocytes/macrophages from healthy donors; it contains no FMT cohort, no patient serum cytokine measurements, and no statement about CCL2/MCP-1, CXCL8/IL-8 or IL-18 levels changing after treatment or being associated with anti-PD-1 outcomes. The closest passages are the Results section 'Recruitment of monocytes by CAFs might be mediated by MCP-1 as well as SDF-1 cytokines' (blocking MCP-1 reduced monocyte migration in vitro) and the Discussion on PD-1+ TAMs citing Gordon et al. and Topalian et al., neither of which addresses circulating cytokine change or immunotherapy outcome association. Searched: 'CCL2 MCP-1 CXCL8 IL-18 negative outcomes anti-PD-1' and 'fecal microbiota transplantation responders serum cytokines' — no supporting passage. (LLM, conf=0.75)
- Not checked yetcites [33] Terme M, Cancer Res. 71, 5393– 5399 (2011). 21724589 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
28 more claims
Create a free account to see all 56 claims and to verify the 17 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In two proof-of-concept trials with a total of 26 patients, responder-derived fecal microbiota transplantation (FMT) overcame PD-1 resistance in a third of patients with melanoma, suggesting that microbiome modulation could improve responsiveness to anti-PD-1 ICB10,11.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This concurs with another clinical trial with a similar FMT-ICB design in which Akk was also associated with response to ICB post-FMT (Davar et al., 2021).”
From Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment (2021) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Davar et al. (2021) found that combining FMT with anti-PD-1 therapy in refractory melanoma patients led to meaningful changes in gut microbial composition, increased activation of CD8+ natural killer-like T cells, recirculation of mucosa-associated invariant T cells, and distinct metabolic shifts associated with enhanced antitumor responses.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of two phase 1 clinical studies NCT03341143 and NCT03353402 showed responder-derived FMT effectively relieved the resistance to α-PD-1/PD-L1 in some melanoma patients, having implications for modulating gut microbiota in cancer immunotherapy [26, 317].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
33 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Cited by
Items 701–800 of 1,002
Promising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou, P., Lopes, C. D. H., & Spreafico, A. (2023) · Cells · doi:10.3390/cells13010019 · Cited by 16
“In addition to the role of gut microbiome in ICI responsiveness [217,233,234], imbalances in the composition or function of gut microbes has also been implicated in ICI toxicity, specifically in patients with melanoma [233].”
BackgroundMeraz-Torres, F., Niessner, H., Plöger, S., Riel, S., Schörg, B. F., Casadei, N., Kneilling, M., Schaller, M., Flatz, L., Maček, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02941-5 · Cited by 15
“However, alternatives are sparse and essentially include enrollment in clinical trials such as TIL therapy [11] or fecal microbiota transplantation [12, 13], as well as chemotherapy.”
BackgroundPreclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice
Hou, X., Liu, S., Zeng, Z., Wang, Z., Ding, J., Chen, Y., Gao, X., Wang, J., Xiao, G., Li, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116669 · Cited by 15
Ji, G., Zhao, J., Si, X., & Song, W. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115345 · Cited by 18
Meng, Y., Sun, J. Y., & Zhang, G. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104403 · Cited by 16
Dravillas, C. E., Coleman, S. S., Hoyd, R., Caryotakis, G., Denko, L., Chan, C. H. F., Churchman, M. L., Denko, N. C., Dodd, R. D., Eljilany, I., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0170 · Cited by 21
“Altering the gut microbiome via responder-derived fecal microbiota transplantation has been shown to induce a clinical response to anti-PD1 treatment in patients with melanoma (46, 47).”
BackgroundLi, D., Lan, X., Xu, L., Zhou, S., Luo, H., Zhang, X., Yu, W., Yang, Y., & Fang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1552010 · Cited by 20
Overcoming hurdles in cancer immunotherapy
York, A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00343-3 · Cited by 15
Host Microbiomes in Tumor Precision Medicine: How far are we?
D’Amico, F., Barone, M., Tavella, T., Rampelli, S., Brigidi, P., & Turroni, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220105121754 · Cited by 17
Baruch, E. N., Gaglani, T., & Wargo, J. A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211045853 · Cited by 17
Pharmacomicrobiomics in precision cancer therapy: bench to bedside
Ngoc, K. L., Pham, T. T. H., Nguyen, T. K., & Huong, P. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428420 · Cited by 20
Chandrasekaran, P., Krausz, M., Han, Y., Mitsuiki, N., Gabrysch, A., Nöltner, C., Proietti, M., Heller, T., Grou, C., Calderon, V., et al. (2025) · Microbiome · doi:10.1186/s40168-025-02028-7 · Cited by 16
“Similarly, two clinical trials demonstrated that FMT can promote therapeutic response in patients with immunotherapy-refractory melanoma [52, 53].”
Zhang, H., Lee, B. J. Y., Wang, T., Xiang, X., Tan, Y., Han, Y., Bi, Y., Zhi, F., Wang, X., He, F., et al. (2025) · hLife · doi:10.1016/j.hlife.2025.04.004 · Cited by 21
“Additionally, the transfer of fecal matter from individuals who respond well to treatment has been shown to boost thesuc-cess of anti-PD-1 therapies in melanoma patients [93,94].”
The microbial landscape of tumors: a deep dive into intratumoral microbiota
Asgharzadeh, S., Pourhajibagher, M., & Bahador, A. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1542142 · Cited by 20
Zhou, P., Zhang, W., Liao, Y., Zhai, Z., Lu, S., Jiang, S., Hu, W., & Gong, W. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002573 · Cited by 18
The microbiota in radiotherapy-induced cancer immunosurveillance
Chen, J., Deutsch, É., Kroemer, G., Galluzzi, L., & Zitvogel, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01052-8 · Cited by 19
Gao, P., Li, X., Duan, Z., Wang, Y., Li, Y., Wang, J., Luo, K., & Chen, J. (2025) · MedComm · doi:10.1002/mco2.70274 · Cited by 21
“…capacity and intrinsic immunostimulatory pathogen-associated molecular patterns (PAMPs) to enhance antitumor immunity and potentiate immunotherapy [285, 286]; (5) exploring immune resistance-associated genes: recent studies have shown that knocking down or overexpressing certain genes can…”
The multi-kingdom cancer microbiome
Dohlman, A. B., Pan, X., Zitvogel, L., & Iliev, I. D. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02103-7 · Cited by 18
“These strategies have shown particular promise in the context of immune checkpoint blockade 127,132,139,140,166,183–186 .”
Rauber, C., Roberti, M. P., Vehreschild, M. J. G. T., Tsakmaklis, A., Springfeld, C., Teufel, A., Ettrich, T. J., Jochheim, L. S., Kandulski, A., Missios, P., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-097802 · Cited by 18
An Engineered Probiotic Consortium Based on Quorum‐Sensing for Colorectal Cancer Immunotherapy
Guo, Y., Gao, M., Wang, L., Yuan, H., Yin, J., Wu, J., Gao, X., Zhu, Z., Zhang, Y., Wang, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202512744 · Cited by 21
Ramesh, A. I., Subbarayan, R., Shrestha, R., & Adtani, P. (2026) · Cancer Reports · doi:10.1002/cnr2.70455 · Cited by 32
Gut-Heart Axis in Myocardial Repair: Mechanisms, Cross-Organ Networks, and Therapeutic Opportunities
Chen, H.-C., Tang, T. W.-H., Pasaribu, S. N. N., Wu, D.-C., Rey, F. E., & Hsieh, P. C. H. (2026) · Circulation Research · doi:10.1161/circresaha.125.326978 · Cited by 15
Microbial metabolites in tumor epigenetic regulation
Zhang, W., Zhang, H., Liao, Y., Jiang, S., Zhang, H., Huang, C., Song, Z., Zhao, R., Lü, P., Kang, X., et al. (2026) · iMeta · doi:10.1002/imt2.70115 · Cited by 19
Cancer evolution: Special focus on the immune aspect of cancer
Hu, X., Chen, Z., Wang, Z., & Xiao, Q. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.006 · Cited by 15
Zou, Y., & Yaguchi, T. (2023) · Experimental Dermatology · doi:10.1111/exd.14750 · Cited by 15
Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology
Foster, J., Alonso, M. M., Sayour, E. J., Davidson, T. B., Persson, M. L., Dun, M. D., Kline, C., Mueller, S., Vitanza, N. A., & van der Lugt, J. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100909 · Cited by 14
Bouferraa, Y., Fares, C., Zerdan, M. B., & Kennedy, L. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119702 · Cited by 15
“The responders showed an increase in the abundance of Firmicutes (Lachnospiraceae and Ruminococcaceae families) and Actinobacteria (Bifidobacteriaceae and Coriobacteriaceae families) taxa that were previously linked to the response to anti-PD-1, as well as increased activation of CD8+ T cells and a decrease in the fre…”
BackgroundResultInfluentialDougan, M. L. (2023) · Immunological Reviews · doi:10.1111/imr.13239 · Cited by 17
Translational research in head and neck cancer: Molecular and immunological updates
Kumai, T., Shinomiya, H., Shibata, H., Takahashi, H., Kishikawa, T., Okada, R., Fujieda, S., & Sakashita, M. (2023) · Auris Nasus Larynx · doi:10.1016/j.anl.2023.08.006 · Cited by 15
Heterogeneity of the tumor immune microenvironment and clinical interventions
Jin, Z., Zhou, Q., Cheng, J., Jia, Q., & Zhu, B. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1015-9 · Cited by 15
Metformin facilitates anti-PD-L1 efficacy through the regulation of intestinal microbiota
Zhao, X., Liu, C., Peng, L., & Wang, H. (2023) · Genes and Immunity · doi:10.1038/s41435-023-00234-7 · Cited by 15
“After receiving fecal microbiota transplantation from the PD-1/PD-L1 antibody-sensitive patients, patients with poor anti-PD-1/PD-L1 treatment response showed signi fi cant increased response [14].”
Self-citationVongsavath, T., Rahmani, R., Tun, K. M., & Manne, V. (2024) · Cancers · doi:10.3390/cancers16030499 · Cited by 16
“PFS in patients with disease control was 14.0 months [24].”
BackgroundInfluentialTargeting gut microbiota for immunotherapy of diseases
Yu, Y., Liu, X., Liao, C., Yu, R., Wang, X., Li, M., & Wang, Y. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03770-x · Cited by 15
“In addition, metabolites of microorganisms modulate cancer progression by modifying the tumor microenvironment (TME), affecting immune cell function and cytokine levels (Davar et al. 2021).”
Rashidi, A., Ebadi, M., Rehman, T. U., Elhusseini, H., Kazadi, D., Halaweish, H., Khan, M. H., Hoeschen, A. L., Cao, Q., Luo, X., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0138 · Cited by 16
“Fecal microbiota transplantation (FMT) from healthy donors has been used to promote response to immune checkpoint inhibitor therapy (2, 3) and abrogate affecting nearly half of all patients and carrying an approximately 20% risk of mortality (6).”
MethodThe gut microbiome and the brain
Rykalo, N. A., Riehl, L., & Kress, M. (2024) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000717 · Cited by 16
Fecal microbiota transplantation-current perspective on human health
Cao, Z., Gao, T., Bajinka, O., Zhang, Y., & Yuan, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1523870 · Cited by 19
Roichman, A., Reyes‐Castellanos, G., Chen, Z., Chen, Z., Mitchell, S. J., MacArthur, M. R., Sawant, A., Levett, L., Powers, J. R., Burgo, V., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4378 · Cited by 16
“FMT from ICB responders has shown promise in some patients with melanoma for improving response to ICB, whereas other patients did not respond favorably (8).”
Anderson, R., Blidner, A. G., & Rapoport, B. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.676399 · Cited by 14
Gut Microbiota in Colorectal Cancer: Associations, Mechanisms, and Clinical Approaches
Pleguezuelos‐Manzano, C., Puschhof, J., & Clevers, H. C. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-095211 · Cited by 19
CRISPR Screens to Identify Regulators of Tumor Immunity
LaFleur, M. W., & Sharpe, A. H. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-094725 · Cited by 16
Issa, M., Tang, J., Guo, Y., Coss, C. C., Mace, T. A., Bischof, J. J., Phelps, M. A., Presley, C. J., & Owen, D. H. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2094772 · Cited by 15
“Perhaps most impressive was a trial showing that fecal microbiota transplant from ICI responders could overcome resistance to ICI in some non-responders [151].”
Liu, L., Zhang, T., Sui, Y., Li, G., Liu, L., Lu, T., Tan, H., Sun, B., Li, X., & Li, L. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106035 · Cited by 16
The potential of fecal microbiota transplantation in oncology
Lythgoe, M. P., Ghani, R., Mullish, B. H., Marchesi, J. R., & Krell, J. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.10.003 · Cited by 14
JAMS - A framework for the taxonomic and functional exploration of microbiological genomic dataPreprint
McCulloch, J. A., Badger, J. H., Cannon, N., Rodrigues, R. R., Valencia, M. E., Barb, J. J., Fernandes, M. R., Balaji, A. K., Crowson, L., Ó’hUigín, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.03.531026 · Cited by 16
Self-citationda Silva, I. P., Zimmer, L., Blay, J., Maio, M., Larkin, J., Grimm, M., Puri, S., Butler, M. O., Patel, S. P., Thakkar, P. K., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105833 · Cited by 13
From immune exclusion to exhaustion: tumor microenvironment drives therapy response
Maletin, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1785587 · Cited by 17
“…to PD-1/PD-L1 therapy across tumor types, and interventional approaches such as fecal microbiota transplantation (FMT) have demonstrated that microbiome modulation can overcome anti – PD-1 resistance in subsets of melanoma patients, supporting a causal role in at least some settings (218, 219).”
Training the microbiota to increase immune checkpoint blockade and to reduce toxicity
Rescigno, M. (2023) · European Journal of Immunology · doi:10.1002/eji.202250183 · Cited by 15
The Gut Microbiome and Metastatic Renal Cell Carcinoma
Meza, L., Feng, M., Lee, K., Sperandio, R., & Pal, S. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041502 · Cited by 12
“Moreover, similar concepts have already been successfully implemented in cohorts of immunotherapy-refractory patients with melanoma [56,57].”
BackgroundThe Interaction between Gut Microbiota and Host Amino Acids Metabolism in Multiple Myeloma
Yang, Q. Z., Wei, Y., Zhu, Y., Guo, J., Zhang, J., He, Y., Li, X., Liu, J., & Zhou, W. (2023) · Cancers · doi:10.3390/cancers15071942 · Cited by 17
The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman, D. D., Hurd, D. E., & Davar, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01431-3 · Cited by 14
Self-citationMicrobiome modulates immunotherapy response in cutaneous squamous cell carcinoma
Voigt, A. Y., Walter, A., Young, T. H., Graham, J. P., Bittencourt, B. M. B., Pulido, Á. D. M., Prieto, K., Tsai, K. Y., Sundberg, J. P., & Oh, J. (2023) · Experimental Dermatology · doi:10.1111/exd.14864 · Cited by 13
Clinical Network Systems Biology: Traversing the Cancer Multiverse
Mambetsariev, I., Fricke, J., Gruber, S., Tan, T., Babikian, R., Kim, P., Vishnubhotla, P., Chen, J., Kulkarni, P., & Salgia, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134535 · Cited by 9
“Microbiome discoveries have resulted in novel techniques of fecal microbiota transplants and have been shown in advanced melanoma to help immunotherapy-resistant patients overcome anti-PD-1 resistance [81].”
BackgroundNeoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
Conroy, M. R., Dennehy, C., & Forde, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107314 · Cited by 13
Ma, L., Song, J., Chen, X., Dai, D., Chen, J., & Zhang, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20591 · Cited by 16
“The human gut microbiota is a distinctive system that subtly influences host metabolism and immunity [9].”
BackgroundInfluence of tumor mycobiome on cancer pathogenesis (Review)
Liu, W., Li, Z., Li, X., Cao, H., Jiang, H., Niu, Q., & Hu, B. (2023) · Oncology Letters · doi:10.3892/ol.2023.14128 · Cited by 13
Gut microbiota in cancer: insights on microbial metabolites and therapeutic strategies
Chen, Y., Wang, X., Ye, Y., & Ren, Q. (2023) · Medical Oncology · doi:10.1007/s12032-023-02249-6 · Cited by 14
“Furthermore, transferring the microbiota from patients who respond positively to specific therapeutic agents to non-responsive patients can enhance drug efficacy and overcome resistance [56, 57].”
Vu, T. T., Kim, K., Manna, M., Thomas, J. W., Remaily, B., Montgomery, E. J., Costa, T., Granchie, L., Xie, Z., Guo, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107048 · Cited by 14
The Microbiome Matters: Its Impact on Cancer Development and Therapeutic Responses
Chung, I.-Y., Kim, J. H., & Koh, A. (2024) · The Journal of Microbiology · doi:10.1007/s12275-024-00110-7 · Cited by 15
“…ICI responders (NCT03353402, NCT03341143) or healthy donors (NCT03772899) contributes to an improved response to anti-PD-1 immunotherapy in melanoma patients, showing elevated microbial taxa linked to positive responses to PD-1 blockade (Baruch et al., 2021; Davar et al., 2021; Routy et al., 2023).”
Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?
Snethlage, C. M. F., de Wit, D. F., Wortelboer, K., Rampanelli, E., Hanssen, N. M. J., & Nieuwdorp, M. (2024) · Immunological Reviews · doi:10.1111/imr.13345 · Cited by 14
“The use of FMT as an add on therapy has previously studied in the field of checkpoint inhibition in melanoma treatment, 152 here they found that when patients did not respond to anti-programmed cell death protein 1 therapy, altering gut microbiota through FMT could induce therapeutic response and…”
The Role of Bacteria in Central Nervous System Tumors: Opportunities and Challenges
Zhang, R., Li, X., & Zhang, S. (2024) · Microorganisms · doi:10.3390/microorganisms12061053 · Cited by 13
“For instance, Ashley A. Hibberd et al. observed an increase in butyrate-producing flora in the feces, tumor mucosa, and non-tumor mucosa following oral probiotics given to patients with colon cancer.”
Self-citationTargeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review
David, A., & Ari, S. L. (2024) · Integrative Cancer Therapies · doi:10.1177/15347354241269870 · Cited by 16
“8,14,19,25 A 2021 systematic review found a correlation between an enriched abundance in the Firmicutes with both response to ICBs and incidence of AE.”
BackgroundGut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer
Okazawa‐Sakai, M., Sakai, S. A., Hyodo, I., Horasawa, S., Sawada, K., Fujisawa, T., Yamamoto, Y., Boku, S., Hayasaki, Y., Isobe, M., et al. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2025.36.e38 · Cited by 14
Yi, D., Li, T., Xiao, Y., Zhang, X., Hao, Q., Zhang, F., Qiu, T., Yang, G., Sun, X., Dong, Y., et al. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10728 · Cited by 16
“96 Recently, FMT combined with tislelizumab and fruquintinib was revealed to exert favorable anti-tumor efficacy and acceptable safety in refractory metastatic colorectal cancer.”
The therapeutic promise of probiotic Bacteroides fragilis (BF839) in cancer immunotherapy
Peng, K., Li, Y., Yang, Q., Yu, P., Zeng, T., Lin, C., Deng, Y., & Chen, J. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1523754 · Cited by 17
Toward the development of defined microbial therapeutics
Li, Y., & Honda, K. (2021) · International Immunology · doi:10.1093/intimm/dxab038 · Cited by 14
ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy
Shen, L., Ye, Y., Sun, H., & Su, B. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.002 · Cited by 13
Mjaess, G., Karam, A., Aoun, F. Y., Albisinni, S., & Roumeguère, T. (2021) · Cancer · doi:10.1002/cncr.33893 · Cited by 14
“The first study was written by Davar et al.6 The authors have shown that FMT induces changes in and reprogramming of the tumor microenvironment that help to overcome resistance to anti– PD1 treatment; it provided a clinical benefit to 6 of 15 included patients (median 16 Cancer January 1, 2022 overall survival [OS] an…”
The gut microbiota can be a potential regulator and treatment target of bone metastasis
Contino, K. F., Yadav, H., & Shiozawa, Y. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114916 · Cited by 17
Wardill, H. R., Chan, R. J., Chan, A., Keefe, D. M. K., Costello, S. P., & Hart, N. H. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-06948-0 · Cited by 16
“In fact, promising data from two small clinical studies (1 study n = 15 with clinical benefit in 6 of 15 patients, and the other study n = 10) [12, 13] show faecal microbiota transplant (FMT)—a method that enables the composition of the gut microbiome to be changed by transferring the entire gut microbiota from one ho…”
BackgroundNi, Z., Wang, S., Li, Y., Zhou, L., Zhai, D., Xia, D., & Yu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932197 · Cited by 13
“In addition, FMT can be applied to overcome resistance to antiprogrammed death protein 1 (PD-1) therapy in patients with melanoma or inhibit the decline of endogenous insulin in patients with type 1 diabetes and other diseases (Baruch et al., 2021; Davar et al., 2021; De Groot et al., 2021).”
BackgroundNutrition and Microbiome Interactions in Human Cancer
Daschner, P. J., Ross, S., Seifried, H. E., Kumar, A., & Flores, R. (2022) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2022.10.004 · Cited by 14
The Microbiome and Liver Cancer
Myojin, Y., & Greten, T. F. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000646 · Cited by 13
Standards for fecal microbiota transplant: Tools and therapeutic advances
Belotserkovsky, I., Stabryla, L. M., Hunter, M. E., Allegretti, J. R., Callahan, B. J., Carlson, P. E., Daschner, P. J., Goudarzi, M., Guyard, C., Jackson, S. A., et al. (2024) · Biologicals · doi:10.1016/j.biologicals.2024.101758 · Cited by 14
Wang, X., Geng, Q., Jiang, H., Yue, J., Qi, C., & Qin, L. (2025) · BMC Immunology · doi:10.1186/s12865-025-00710-x · Cited by 14
Zhang, P., Pan, J., Lin, S., Peng, B., Zhang, J., Zhang, J., Xu, L., Lai, Y. L., Yu, H., & Xu, Z. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115620 · Cited by 15
Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 18
Zheng, S., Li, K.-Z., Feng, G., Wang, Y.-T., Jia-ning, W. A. N. G., Li, S., & Sun, Y.-D. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02513-5 · Cited by 17
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
Silva, C. A. C., Machaalani, M., Saliby, R. M., Zhong, C., Xie, W., Pasolli, E., Piccinno, G., Dalban, C., Fidelle, M., Meurisse, A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04067-x · Cited by 17
“…such as fecal microbial transplantation from patients who benefited from ICI or from healthy volunteers, in individuals with metastatic melanoma 13–16 , lung cancer 17 and renal cell carcinoma (RCC) 11,18,19 , or oral administration of the probiotic Clostridium butyricum strain CBM 588 in…”
The tumor microenvironment: adding pieces to the puzzle
Aguilar‐Cázares, D., Perez-Medina, M., Benito-Lopez, J. J., Galicia-Velasco, M., Meneses-Flores, M., Camarena, Á., & López-González, J. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1731338 · Cited by 16
Strain-level genetic heterogeneity and colonization dynamics drive microbiome therapeutic efficacy
Chen, K., Liu, Y., Rong, J., Dai, N., Xu, C., Li, H., Zhong, L., Wang, B., Ji, Z., Xie, S., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.02.002 · Cited by 12
Gut microbes as biomarkers of ICI response — sharpening the focus
Bhutiani, N., & Wargo, J. A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00634-0 · Cited by 12
From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer
Seo, Y. D., & Wargo, J. A. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101039 · Cited by 13
Cheng, X., Li, X., Yang, X., Fang, S., Wang, Z., Liu, T., Zheng, M., Zhai, M., Yang, Z., & Shen, T. (2023) · Cureus · doi:10.7759/cureus.42347 · Cited by 22
“Bacteroides uniforms, which was reported to enrich in ICI non-responders' stool samples [13], decreased from R1 of 15% to R5 of 6.”
BackgroundPoletto, S., Paruzzo, L., Nepote, A., Caravelli, D., Sangiolo, D., & Carnevale‐Schianca, F. (2023) · Cancers · doi:10.3390/cancers16010101 · Cited by 15
Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy
Han, Y., Zhang, Z., Zhao, K., Zhang, Y., Yin, X., Zhu, G., Wang, Z., Yan, X., Li, X., He, T., et al. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.110774 · Cited by 14
Gut Microbial Dysbiosis in the Pathogenesis of Leukemia: An Immune-based Perspective.
Goswami, M., & Bose, P. D. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104211 · Cited by 12
Tong, L., Wan, Y., Shi, X., Liu, X., Liu, Z., Li, Y., Zhang, Y., Luo, D., & Zhu, J. (2024) · Cancer Control · doi:10.1177/10732748241253959 · Cited by 15
Alotaibi, F., Albalawi, I. A. S., Anis, A. M., Alotaibi, H., KHASHWAYN, S. A., Alshammari, K. M., & Al‐Tawfiq, J. A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1415093 · Cited by 16
Chambers, L., Grencewicz, D. J., & Spakowicz, D. J. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.07.015 · Cited by 13
Zhang, H., Liu, C., Wang, S., Wang, Q., Xu, F., Jiang, H., Li, X., Luo, C., Zhang, L., Hou, F., et al. (2024) · eLife · doi:10.7554/elife.95453.3 · Cited by 21
Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
“Prebiotics, probiotics, postbiotics, targeted antibiotics, diet-based therapies, and fecal microbiota transplantation (FMT) are promising approaches to be used [47, 48].”
Vogrig, A., Dentoni, M., Florean, I., Cellante, G., Domenis, R., Iacono, D., Pelizzari, G., Rossi, S., Damato, V., Fabris, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548897 · Cited by 23
“It is likely that primary resistance to ICIs could be related to dysbiosis itself, as con fi rmed by the fact that fecal microbiota transplant from ICI responders to non-responders was able to overcome resistance in a subset of patients (78, 79).”
Gut microbiota affects PD-L1 therapy and its mechanism in melanoma
Liu, S., Liu, J., Mei, Y., & Zhang, W. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04018-y · Cited by 14
“The tumor microenvironment is the soil for tumor cell growth, and at the same time, it is also an accomplice to help tumor cells escape immune detection [12].”
InfluentialImpacts of non-nutritive sweeteners on the human microbiome
Crakes, K. R., Questell, L., Soni, S., & Suez, J. (2025) · Immunometabolism · doi:10.1097/in9.0000000000000060 · Cited by 17
“As a notable example, the microbiome has been shown to mediate clinical responsiveness to anti-cancer immunotherapies [84–86] , which can be improved upon microbiome modulation using fecal microbiome transplantations from clinical responders or healthy donors [87–90] .”
Gut microbiota: Role and Association with Tumorigenesis in Different Malignancies
Ali, A., Ara, A., & Kashyap, M. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07357-6 · Cited by 12
Rakotonirina, A., Galpérine, T., & Allémann, É. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2095901 · Cited by 16
“ity in patients with anti-PD-1 refractory metastatic melanoma [162,163], which is promising as a future use of this treatment.”
BackgroundPiazzesi, A., & Putignani, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.958346 · Cited by 14
Drommi, F., Calabrò, A., Vento, G., Pezzino, G., Cavaliere, R., Omero, F., Muscolino, P., Granata, B., D’Anna, F., Silvestris, N., et al. (2023) · Cancers · doi:10.3390/cancers15112893 · Cited by 14
Hes, C., & Jagoe, R. T. (2023) · BJC Reports · doi:10.1038/s44276-023-00008-8 · Cited by 16
“It remains to be seen whether the association between the abundance of certain taxa in stool and ICI response is causative in humans and intervention trials using targeted faecal transplantation are ongoing (e.g., www.clinicaltrials.gov: NCT05251389) [27, 28].”
BackgroundMicrobiota-based biomarkers and therapeutics for cancer management
Wu, W. K. K., & Yu, J. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00879-9 · Cited by 13
Metadata
- Authors
- Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H., Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., Morgun, A., Vujkovic-Cvijin, I., Wang, H., Borhani, A. A., Schwartz, M. B., Dubner, H. M., Ernst, S. J., Rose, A., Najjar, Y. G., Belkaid, Y., Kirkwood, J. M., Trinchieri, G., & Zarour, H. M.
- Affiliations
- University of Pittsburgh (US)
- National Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
- Oregon State University (US)
- National Institutes of Health (US)
- Corresponding author
- Davar, Diwakar
- Dzutsev, Amiran K.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- ORCID
- Davar, Diwakar
- Dzutsev, Amiran K.
- McCulloch, John A.
- Rodrigues, Richard R.
- Chauvin, Joe-Marc
- Morrison, Robert M.
- Pagliano, Ornella
- Zidi, Bochra
- Zhang, Shuowen
- Badger, Jonathan H.
- Vetizou, Marie
- Cole, Alicia M.
- Fernandes, Miriam R.
- Prescott, Stephanie
- Costa, Raquel G. F.
- Balaji, Ascharya K.
- Morgun, Andrey
- Vujkovic-Cvijin, Ivan
- Wang, Hong
- Borhani, Amir A.
- Schwartz, Marc B.
- Dubner, Howard M.
- Najjar, Yana G.
- Belkaid, Yasmine
- Kirkwood, John M.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 595-602
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8097968
- OpenAlex
- W3126208996
- Cited by
- 1,781
- References
- 54
- Citations by year
- 2026: 396 · 2025: 328 · 2024: 315 · 2023: 316 · 2022: 282 · 2021: 141
- FWCI
- 97.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA228181, CA222203)
- Melanoma Research Foundation (MRFBC 2020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- fecal microbiota transplantation, anti-PD-1 therapy, melanoma, immunotherapy resistance, gut microbiota, CD8+ T cell activation, interleukin-8, myeloid cells, immunosuppression
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Humans, Lymphocyte Activation, Melanoma, Skin Neoplasms, Interleukin-8, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Myeloid Cells, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.